OKI-179 + Binimetinib for Melanoma
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a combination of two oral medications, OKI-179 and binimetinib, in patients with specific genetic mutations in their cancer. It targets those with RAS pathway mutations and NRAS-mutated Melanoma. The treatment works by blocking signals that help cancer cells grow and divide. Binimetinib is a selective MEK1/2 inhibitor approved in 2018 for the treatment of metastatic melanomas with BRAF and NRAS mutations.
Who Is on the Research Team?
Ryan Sullivan, MD
Principal Investigator
Massachusetts General Hospital
Are You a Good Fit for This Trial?
This trial is for adults with advanced solid tumors in the RAS pathway or NRAS-mutated melanoma. They must have normal organ and marrow function, be able to swallow oral meds, and not be pregnant or nursing. Exclusions include hypersensitivity to MEK inhibitors, certain eye conditions, uncontrolled heart disease, severe infections like HIV/AIDS, recent major surgery or chemotherapy.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment Phase 1b
Participants with activating mutations in the RAS pathway receive a combination of oral OKI-179 and binimetinib
Treatment Phase 2
Participants with NRAS-mutated Melanoma receive a combination of oral OKI-179 and binimetinib
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Binimetinib
- OKI-179
Binimetinib is already approved in United States, European Union, Canada, Japan for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
OnKure, Inc.
Lead Sponsor